ANALYSTS have suggested Omega Diagnostics may sell around £2 million of its highly-anticipated HIV test in 2015.

Edison Investment Research said it believes pilot studies for the CD4 test, which sees if white blood cells have fallen to a level where retroviral drug treatment is needed, could start in the first half of next year with "significant sales" in the following 12 months.

The research note also indicates a full launch for Omega's 40 automated allergy tests for the iSYS system used in laboratories around the world may now be in mid-2015.

Edison predicted revenue at Omega in its 2015 financial year will be more than £14m with profit before tax coming in around £2.4m.

The company is expected to post revenue of around £11.5m in the 12 months to March 2014 with profits of £700,000.